Physician profile
Paul A Jones
NPI 1689651341
$5,056.00
in general payments reported to CMS, 2019-2025
38 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $527 · 2021: $1,021 · 2022: $1,501 · 2023: $314 · 2024: $16.22 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $675.33 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $643.55 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $378.67 | 2019-2023 | Lifevest |
| Pfizer INC. | $327.39 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.70 | 2019-2023 | Jardiance |
| Siemens Medical Solutions USA, INC. | $299.50 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $252.70 | 2021-2023 | Opsumit, Uptravi |
| Amgen INC. | $207.93 | 2019-2022 | |
| Endologix LLC | $181.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $179.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $171.63 | 2021-2023 | Verquvo |
| Medtronic Vascular, INC. | $163.31 | 2019-2020 | |
| Abiomed | $118.23 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $114.23 | 2019 | |
| Bolton Medical INC | $113.74 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $112.25 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $105.58 | 2019-2023 | Onpattro |
| Boston Scientific Corporation | $85.98 | 2020-2023 | Eluvia |
| Esperion Therapeutics, INC. | $79.61 | 2021 | |
| Abbott Laboratories | $74.81 | 2021-2022 | |
| Chiesi USA, INC. | $71.91 | 2019-2020 | |
| Shockwave Medical, INC | $53.32 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $52.86 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $37.33 | 2020-2022 | |
| Portola Pharmaceuticals, LLC | $24.97 | 2019 | |
| Philips North America LLC | $24.77 | 2020 | |
| Vifor Pharma, INC. | $24.44 | 2019 | |
| Amarin Pharma, INC. | $24.37 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2019 | |
| Medtronic, INC. | $17.75 | 2021 | |
| Cook Medical LLC | $16.22 | 2024 | Cook |
| Ekos Corporation | $15.71 | 2019 | |
| Astellas Pharma US INC | $15.18 | 2019 | |
| Elutia, INC. | $13.11 | 2022 | |
| Terumo Medical Corporation | $12.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 | |
| Janssen Scientific Affairs, LLC | $8.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.